Patents by Inventor Andres Dulcey Garcia

Andres Dulcey Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF LOW DOSE EMETINE FOR INHIBITION OF HUMAN CYTOMEGALOVIRUS (HCMV)
    Publication number: 20230000857
    Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.
    Type: Application
    Filed: February 11, 2022
    Publication date: January 5, 2023
    Inventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
  • Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
    Patent number: 11253511
    Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 22, 2022
    Assignees: The Johns Hopkins University, THE UNITED STATES OF AMERICA, as represented by th
    Inventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
  • USE OF LOW DOSE EMETINE FOR INHIBITION OF HUMAN CYTOMEGALOVIRUS (HCMV)
    Publication number: 20190022083
    Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and CN compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.
    Type: Application
    Filed: January 4, 2017
    Publication date: January 24, 2019
    Inventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu